Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 9, September, p. 1249–1255

doi: 10.17219/acem/68364

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Single-nucleotide polymorphisms of APE1 associated with risk and prognosis of vitiligo in a Han Chinese population

Xian-Jin Chen1,A,B,C,D,E,F, Li-Li Chang2,B,C,E,F, Qi Wang1,B,C,E,F, Chun-Yu Han1,C,E,F, Wen-Jun Li3,C,E,F, Fu-Jun Tian4,A,B,C,D,E,F, Li-Qian Liu4,C,E,F

1 Department of Dermatology, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China

2 Department of Intensive Care Unit, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China

3 Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, China

4 Department of Dermatology, Linyi People’s Hospital, China


Background. The single-nucleotide polymorphisms (SNPs) of apurinic/apyrimidinicendonuclease 1 (APE1), which has been implicated in cancers and the DNA base excision repair (BER) process, have not been thoroughly investigated in association with the risks of oxidative stress-related vitiligo.
Objectives. The aim of this study is to investigate associations between APE1 single-nucleotide polymorphisms 141T >G and 1349T >G and risk and prognosis of vitiligo.
Material and Methods. From June 2013 to June 2015, a total of 460 vitiligo patients were randomly recruited as a case group; 200 of these patients received narrow bound ultraviolet B (NB-UVB) treatment. Meanwhile, 460 healthy controls were included as a control group. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed to explore the distribution frequencies of genotypes.
Results. Significant differences were detected between the case group and the control group in the frequencies of the 141T >G and 1349T >G genotypes. At 141T >G, compared with patients carrying the TG + GG genotype, male patients carrying the TT genotype aged more than 20 years with active non-segmental vitiligo, without a family history of vitiligo or other autoimmune diseases, exhibited an increased risk of vitiligo. Binary logistic regression analysis demonstrated that the TT genotype at 141T >G and the non-TT genotype at 1349T >G were independent risk factors for vitiligo development. At 1349T >G, compared with patients carrying the TT genotype, male patients carrying the TG + GG genotype aged more than 20 years with active non-segmental vitiligo, without a family history of vitiligo or other autoimmune diseases, exhibited an increased risk of vitiligo. Moreover, patients carrying 141TG + GG or 1349 TT genotypes had better photochromic effects, lower cumulative radiation doses, shorter treatment times, and earlier first photochromic times.

Key words

vitiligo, APE1, 141T >G, Asp148Glu, risk of vitiligo

References (32)

  1. Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL-6 and IL-8. J Invest Dermatol. 2012;132(11):2601–2609.
  2. Larhmam MA, Benjelloun M, Mahmoudi S. Vertebra identification using template matching modelmp and K-means clustering. Int J Comput Assist Radiol Surg. 2014;9(2):177–187.
  3. Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–1212.
  4. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010;20(7):745–754.
  5. Treatment of vitiligo: Advantages and disadvantages, indications for use and outcomes. G Ital Dermatol Venereol. 2011;146(5):373–395.
  6. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84.
  7. Hossani-Madani AR, Halder RM. Topical treatment and combination approaches for vitiligo: New insights, new developments. G Ital Dermatol Venereol. 2010;145(1):57–78.
  8. Lee DY, Kim CR, Park JH. Recurrence after epidermal grafting in segmental vitiligo. Dermatol Surg. 2011;37(11):1707–1708.
  9. Workman M, Sawan K, El Amm C. Resolution and recurrence of vitiligo following excision of congenital melanocytic nevus. Pediatr Dermatol. 2013;30(6):e166–168.
  10. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28(2):86–92.
  11. Simon JD, Peles D, Wakamatsu K, Ito S. Current challenges in understanding melanogenesis: Bridging chemistry, biological control, morphology, and function. Pigment Cell Melanoma Res. 2009;22(5):563–579.
  12. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: Autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17(2):139–140.
  13. Rahmanian S, Taleei R, Nikjoo H. Radiation induced base excision repair (BER): A mechanistic mathematical approach. DNA Repair (Amst). 2014;22:89–103.
  14. Mouret S, Forestier A, Douki T. The specificity of UVA-induced DNA damage in human melanocytes. Photochem Photobiol Sci. 2012;11(1):155–162.
  15. Bardia A, Tiwari SK, Gunisetty S, et al. Functional polymorphisms in XRCC-1 and APE-1 contribute to increased apoptosis and risk of ulcerative colitis. Inflamm Res. 2012;61(4):359–365.
  16. Breton CV, Zhou W, Kile ML, et al. Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis. 2007;28(7):1520–1525.
  17. Al-Attar A, Gossage L, Fareed KR, et al. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer. 2010;102(4):704–709.
  18. M PN. World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.
  19. Faria AR, Tarle RG, Dellatorre G, Mira MT, Castro CC. Vitiligo – Part 2 – classification, histopathology and treatment. An Bras Dermatol. 2014;89(5):784–790.
  20. Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28(3):115–119.
  21. Majid I, Imran S. Targeted ultraviolet B phototherapy in vitiligo: A comparison between once-weekly and twice-weekly treatment regimens. Indian J Dermatol Venereol Leprol. 2015;81(6):600–605.
  22. Oxidative stress level and tyrosinase activity in vitiligo patients. Indian J Dermatol. 2010;55(1):15–19.
  23. Salem MM, Shalbaf M, Gibbons NC, Chavan B, Thornton JM, Schallreuter KU. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: A possible repair mechanism for DNA damage. FASEB J. 2009;23(11):3790–3807.
  24. Wei C, Jian Z, Wang L, et al. Genetic variants of the APE1 gene and the risk of vitiligo in a Chinese population: A genotype-phenotype correlation study. Free Radic Biol Med. 2013;58:64–72.
  25. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells. Base excision repair: The long and short of it. Cell Mol Life Sci. 2009;66(6):981–993.
  26. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: Not only a DNA repair enzyme. Antioxid Redox Signal. 2009;11(3):601–620.
  27. Andreassi MG, Foffa I, Manfredi S, Botto N, Cioppa A, Picano E. Genetic polymorphisms in XRCC1, OGG1, APE1 and XRCC3 DNA repair genes, ionizing radiation exposure and chromosomal DNA damage in interventional cardiologists. Mutat Res. 2009;666(1–2):57–63.
  28. A functional single-nucleotide polymorphism in the catechol-O-methyltransferase gene alter vitiligo risk in a Chinese population. Arch Dermatol Res. 2009;301(9):681–687.
  29. Gu D, Wang M, Wang M, Zhang Z, Chen J. The DNA repair gene APE1 T1349G polymorphism and cancer risk: A meta-analysis of 27 case-control studies. Mutagenesis. 2009;24(6):507–512.
  30. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003;111(15):1843–1850.
  31. Li C, Liu Z, Wang LE, Strom SS, et al. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006;27(9):1894–1901.
  32. Sehgal VN, Srivastava G: Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149–156.